Provided by Tiger Trade Technology Pte. Ltd.

Neurocrine Biosciences

156.76
+2.731.77%
Post-market: 158.531.77+1.13%17:05 EDT
Volume:878.42K
Turnover:137.12M
Market Cap:15.99B
PE:22.98
High:157.03
Open:154.31
Low:153.70
Close:154.03
52wk High:186.12
52wk Low:122.14
Shares:102.00M
Float Shares:100.00M
Volume Ratio:0.81
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.82
EPS(LYR):4.67
ROE:22.09%
ROA:11.70%
PB:4.33
PE(LYR):33.57

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 18

BRIEF-Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics

Reuters
·
May 18

Neurocrine completes Soleno acquisition in USD 2.9 billion deal

Reuters
·
May 18

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

THOMSON REUTERS
·
May 18

Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data Release - Has The Bull Case Changed?

Simply Wall St.
·
May 12

Analysts’ Top Healthcare Picks: Neurocrine (NBIX), Certara (CERT)

TIPRANKS
·
May 11

Soleno Q1 FY26 net income swings to USD 31.38 million; selling, general and administrative expense rises 72% to USD 50.37 million

Reuters
·
May 08

Neurocrine Is Maintained at Buy by Truist Securities

Dow Jones
·
May 07

Neurocrine Biosciences, Inc. : Deutsche Bank Raises Target Price to $155 From $150

THOMSON REUTERS
·
May 07

Neurocrine price target raised to $207 from $190 at Piper Sandler

TIPRANKS
·
May 07

Neurocrine price target raised to $155 from $140 at Truist

TIPRANKS
·
May 07

Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says

MT Newswires Live
·
May 06

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), DENTSPLY SIRONA (XRAY) and Neurocrine (NBIX)

TIPRANKS
·
May 06

Stock Track | Neurocrine Biosciences Soars 5.86% in Pre-market on Positive Crenessity News and Analyst Upgrades

Stock Track
·
May 06

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Fresenius Medical Care (FMS) and American Well (AMWL)

TIPRANKS
·
May 06

Neurocrine Is Maintained at Outperform by Wedbush

Dow Jones
·
May 06

Neurocrine publishes expert guidance on glucocorticoid tapering after starting Crenessity in CAH

Reuters
·
May 06

Morgan Stanley Raises Price Target on Neurocrine Biosciences to $191 From $185, Keeps Equalweight Rating

MT Newswires Live
·
May 06

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction After Initiating Crenessity® (Crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

THOMSON REUTERS
·
May 06

Neurocrine Biosciences : Oppenheimer Raises Target Price to $230 From $220

THOMSON REUTERS
·
May 06